Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands

Molecular and Cellular Biology

Volumn 32, Issue 10, 2012, Pages 1944-1954

  Goetz, Regina ^a   Ohnishi, Mutsuko ^b   Ding, Xunshan ^c   Kurosu, Hiroshi ^c,e   Wang, Lei ^c   Akiyoshi, Junko ^b   Ma, Jinghong ^a   Gai, Weiming ^a   Sidis, Yisrael ^d   Pitteloud, Nelly ^d   Kuro o, Makoto ^c   Razzaque, Mohammed S ^b   Mohammadi, Moosa ^a  

^a University School of Medicine   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAKLOTHO PROTEIN; BETAKLOTHO PROTEIN; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN; KLOTHO CORECEPTOR; KLOTHO PROTEIN; LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALS; BINDING SITES; CELL LINE; FIBROBLAST GROWTH FACTOR 8; GLUCURONIDASE; HUMANS; LIGANDS; PARACRINE COMMUNICATION; PROTEIN ISOFORMS; RATS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84861355961     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06603-11     Document Type: Article

References (77)

1. ADHR Consortium. 2000. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26:345-348.
2. Antoine M, et al. 2006. Fibroblast growth factor 16 and 18 are expressed in human cardiovascular tissues and induce on endothelial cells migration but not proliferation. Biochem. Biophys. Res. Commun. 246:224-233.
3. Asada M, et al. 2009. Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim. Biophys. Acta 1790:40-48.
4. Badman MK, et al. 2007. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5:426-437.
5. Beenken A, Mohammadi M. 2009. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8:235-253.
6. Beenken A, Mohammadi M. 2011. The structural biology of the FGF19 subfamily, p 1-24. In Kuro-oM(ed), Endocrine FGFs and Klothos, 1st ed. Landes Bioscience, Austin, TX.
7. Bottcher RT, Niehrs C. 2005. Fibroblast growth factor signaling during early vertebrate development. Endocr. Rev. 26:63-77.
8. Cantarel BL, et al. 2009. The Carbohydrate-Active EnZymes database (CAZy): an expert resource for glycogenomics. Nucleic Acids Res. 37: D233-D238.
9. Chellaiah AT, McEwen DG, Werner S, Xu J, Ornitz DM. 1994. Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/ FGF-1. J. Biol. Chem. 269:11620-11627.
10. Cole LW, et al. 2008. Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J. Clin. Endocrinol. Metab. 93: 3551-3559.
11. Fisher FM, et al. 2011. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152:2996-3004.
12. Fu L, et al. 2004. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145:2594-2603.
13. Gabrielsson BG, et al. 2002. Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes. Res. 10:608-610.
14. Galman C, et al. 2008. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 8:169-174.
15. Goetz R, et al. 2007. Molecular insights into the Klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 27:3417-3428.
16. Goetz R, et al. 2010. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc. Natl. Acad. Sci. U.S.A. 107:407-412.
17. Hart AW, Baeza N, Apelqvist A, Edlund H. 2000. Attenuation of FGF signalling in mouse β-cells leads to diabetes. Nature 408:864-868.
18. Holt JA, et al. 2003. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17:1581-1591.
19. Ibrahimi OA, et al. 2004. Biochemical analysis of pathogenic liganddependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum. Mol. Genet. 13: 2313-2324.
20. Inagaki T, et al. 2005. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2:217-225.
21. Inagaki T, et al. 2007. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5:415-425.
22. Ito S, et al. 2000. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech. Dev. 98:115-119.
23. Itoh N, Ornitz DM. 2004. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20:563-569.
24. Itoh N, Ornitz DM. 2011. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149:121-130.
25. Jiang J, Prasad K, Lafer EM, Sousa R. 2005. Structural basis of interdomain communication in the Hsc70 chaperone. Mol. Cell 20:513-524.
26. Johnson DE, Lu J, Chen H, Werner S, Williams LT. 1991. The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol. Cell. Biol. 11:4627-4634.
27. Kalinina J, et al. 2009. Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Mol. Cell. Biol. 29:4663-4678.
28. Kharitonenkov A, et al. 2008. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215:1-7.
29. Kharitonenkov A, et al. 2005. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115:1627-1635.
30. Kir S, et al. 2011. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621-1624.
31. Kuro-o, M, et al. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51.
32. Kurosu H, et al. 2007. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282:26687-26695.
33. Kurosu H, et al. 2006. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 281:6120-6123.
34. Kurosu H, et al. 2005. Suppression of aging in mice by the hormone Klotho. Science 309:1829-1833.
35. Li SA, et al. 2004. Immunohistochemical localization of klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct. Funct 29:91-99.
36. Lundasen T, Galman C, Angelin B, Rudling M. 2006. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 260:530-536.
37. Luo Y, et al. 2010. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. J. Biol. Chem. 285:30069-30078.
38. Machado MF, et al. 2009. Regulation and action of fibroblast growth factor 17 in bovine follicles. J. Endocrinol. 202:347-353.
39. Makarenkova HP, et al. 2009. Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. Sci. Signal. 2:ra55.
40. Massague J. 1998. TGF-beta signal transduction. Annu. Rev. Biochem. 67:753-791.
41. Micanovic R, et al. 2009. Different roles of N-and C-termini in the functional activity of FGF21. J. Cell. Physiol. 219:227-234.
42. Miki T, et al. 1992. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc. Natl. Acad. Sci. U.S.A. 89:246-250.
43. Mohammadi M, Olsen SK, Ibrahimi OA. 2005. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16:107-137.
44. Mori K, et al. 2000. Disruption of klotho gene causes an abnormal energy homeostasis in mice. Biochem. Biophys. Res. Commun. 278:665-670.
45. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
46. Ogawa Y, et al. 2007. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. U.S.A. 104:7432-7437.
47. Ohnishi M, Kato S, Akiyoshi J, Atfi A, Razzaque MS. 2011. Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions. FASEB J. 25:2031-2039.
48. Olsen SK, et al. 2003. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J. Biol. Chem. 278:34226-34236.
49. Olsen SK, et al. 2004. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl. Acad. Sci. U.S.A. 101:935-940.
50. Olsen SK, et al. 2006. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev. 20:185-198.
51. Ornitz DM, et al. 1996. Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 271:15292-15297.
52. Orr-Urtreger A, et al. 1993. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev. Biol. 158:475-486.
53. Pitteloud N, et al. 2007. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J. Clin. Invest. 117: 457-463.
54. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M. 2000. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101:413-424.
55. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. 1999. Structural basis for FGF receptor dimerization and activation. Cell 98: 641-650.
56. Portela VM, et al. 2010. Expression and function of fibroblast growth factor 18 in the ovarian follicle in cattle. Biol. Reprod. 83:339-346.
57. Potthoff MJ, et al. 2011. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 13:729-738.
58. Potthoff MJ, et al. 2009. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. U.S.A. 106:10853-10858.
59. Razzaque MS. 2009. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 5:611-619.
60. R&D Systems Immunohistochemistry Laboratory. 2011. FGF17 in human kidney. R&D Systems, Minneapolis, MN. www.rndsystems.com/pdf/mab319/pdf.
61. Schlessinger J, et al. 2000. Crystal structure of a ternary FGF-FGFRheparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6:743-750.
62. Shimada T, et al. 2004. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113:561-568.
63. Stauber DJ, DiGabriele AD, Hendrickson WA. 2000. Structural interactions of fibroblast growth factor receptor with its ligands. Proc. Natl. Acad. Sci. U.S.A. 97:49-54.
64. Tanaka A, et al. 1998. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF8. Cancer Res. 58:2053-2056.
65. Thisse B, Thisse C. 2005. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev. Biol. 287:390-402.
66. Tomlinson E, et al. 2002. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741-1747.
67. Tong X, et al. 2010. Transcriptional repressor E4-binding protein 4 (E4BP4) regulates metabolic hormone fibroblast growth factor 21 (FGF21) during circadian cycles and feeding. J. Biol. Chem. 285:36401-36409.
68. Urakawa I, et al. 2006. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774.
69. Utsugi T, et al. 2000. Decreased insulin production and increased insulin sensitivity in the klotho mutant mouse, a novel animal model for human aging. Metabolism 49:1118-1123.
70. White KE, et al. 2001. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60:2079-2086.
71. Wilkie AO. 2005. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev. 16:187-203.
72. Wolf I, et al. 2008. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27:7094-7105.
73. Wu X, et al. 2008. C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J. Biol. Chem. 283:33304-33309.
74. Yeh BK, et al. 2003. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 100:2266-2271.
75. Yie J, et al. 2009. FGF21 N-and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583:19-24.
76. Zammit C, et al. 2002. Fibroblast growth factor 8 is expressed at higher levels in lactating human breast and in breast cancer. Br. J. Cancer. 86: 1097-1103.
77. Zhang X, et al. 2006. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281:15694-15700.